Stz-induced Diabetes
Stz-induced Diabetes - Related Videos
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
0 Views •
Cited by 69 •
2013
Metabolic memory is the phenomenon by which diabetic complications persist and progress unimpeded even after euglycemia is achieved pharmaceutically. Here we describe a diabetes mellitus zebrafish model which is unique in that it allows for the examination of the mitotically transmissible epigenetic components of metabolic memory in vivo.
04:26
Streptozocin Treatment: A Zebrafish Model of Type 1 Diabetes Mellitus
0 Views •
2023
This video describes the technique of creating a zebrafish model for Type 1 diabetes mellitus with the help of the drug Streptozocin, to study the pathophysiology of diabetic complications and metabolic memory.
10:27
An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
0 Views •
Cited by 3 •
2017
This work presents the methodology of applying high intensity-focused ultrasound to block the action potentials of diabetic neuropathic nerves.
10:43
Transplantation of Pancreatic Islets Into the Kidney Capsule of Diabetic Mice
0 Views •
Cited by 98 •
2007
Our protocol was developed to cleanly and easily deliver islets or cells under the kidney capsule of mice. Cells are concentrated into pellets in the final tubing used for transplanting the cells under the kidney capsule. The ease of this technique reduces stress to the cells and the mouse.
05:45
Rapid Determination of the Thermal Nociceptive Threshold in Diabetic Rats
0 Views •
Cited by 10 •
2012
Here, we describe a rapid reliable and simple procedure to determine the lowest temperature at which rats or mice show nocifensive behavior, i.e. the thermal nociceptive threshold (TNT). This method applies a slowly increasing thermal stimulus allowing precise and reproducible estimation of TNTs with minimum, if any, stress to the animals.
FAQs
Streptozotocin enters pancreatic beta cells through glucose transporter 2, which helps explain the model’s selective effect on insulin-producing tissue. Once inside, STZ promotes DNA alkylation and oxidative stress. These injuries disrupt beta-cell function and can progress to cell death, reducing insulin secretion and producing the metabolic changes required for experimental diabetes studies.
DNA alkylation directly damages genetic material, while oxidative stress adds chemical injury that can impair beta-cell viability and function. Their combined effects help account for the sustained reduction in insulin secretion after STZ exposure. This mechanism allows investigators to examine diabetes resulting from beta-cell injury rather than relying only on changes in circulating glucose.
Dose and administration schedules influence the extent and pattern of beta-cell injury. Depending on these choices, the resulting phenotype may more closely resemble insulin-deficient diabetes or insulin-resistant diabetes. Researchers therefore select and interpret the regimen in relation to the disease feature they intend to study, rather than treating every STZ model as biologically identical.
A typical workflow begins with STZ administration, followed by assessment of whether persistent hyperglycemia develops. Investigators then characterize metabolic or vascular changes and apply the treatment, protective strategy, or beta-cell restoration approach under study. Comparing these outcomes with the diabetic state helps determine whether an intervention improves glucose regulation, complications, insulin action, or beta-cell function.
This model supports studies of diabetes pathophysiology, including how reduced insulin secretion contributes to metabolic disease and related vascular complications. It also provides an experimental setting for evaluating insulin treatments, glucose-lowering therapies, and approaches intended to protect or restore beta-cell function. Its usefulness extends from mechanism-focused experiments to testing potential therapeutic effects.
In medicine, STZ-induced diabetes connects beta-cell injury with measurable metabolic and vascular outcomes. Researchers can use the model to follow persistent hyperglycemia while examining complications and testing interventions designed to improve disease control. Interpreting the findings requires attention to whether the selected dose and schedule produced an insulin-deficient or insulin-resistant phenotype, because that distinction affects clinical relevance.